Todd M. Bauer

First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer

Alice T. Shaw, Todd M. Bauer, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 817 citations · Full text

Medicine, Oncology, Pharmacology +16

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig et al. · Cancer Discovery · 2015 · 796 citations · Full text

Medicine, Molecular Genetics, Oncology +16

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 789 citations

Medicine, Oncology, Medical Oncology +10

Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers

Lori J. Wirth, Eric J. Sherman, Bruce Robinson et al. · New England Journal of Medicine · 2020 · 773 citations · Full text

Medicine, Endocrinology, Oncology +16